drugset / Trial / NCT01354782

Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects

NCT01354782

Phase 1 Completed 32 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective is to assess the pharmacokinetics (PK) of roflumilast and its metabolite roflumilast N-oxide after single and repeated oral administrations of roflumilast 500 μg in healthy Chinese subjects.

Timeline

Start
2011-05
Primary completion
2011-06
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Roflumilast Small molecule 500 ug Oral